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Abstract
Background: Coronary artery disease (CAD) is a complex 
metabolic disorder in which lifestyle and genetic factors are 
known to play key roles in pathogenesis. The paraoxonase 1 
(PON1) enzyme has a defensive effect against CAD progres-
sion, as it safeguards low-density lipoproteins (LDLs) from 
oxidative modifications. The most extensively studied ge-
netic variants in the PON1 gene are Q192R and L55M, which 
have been related with LDL antioxidative activity and risk of 
CAD. Objective: The present case-control study intended to 
examine the Q192R and L55M polymorphisms and their as-
sociation with the risk of CAD patients in north Indians. 
Methods: A total of 872 subjects (412 CAD patients and 460 
controls) were recruited from north India. The PON1 gene 
was amplified and genotypes were studies using PCR-RFLP. 
χ2 analysis was performed to compare genotype/allele fre-
quencies in patients and controls. Results: The present study 
indicated abdominal obesity, elevated body mass index, and 
dyslipidemia with increased levels of total cholesterol and 
triglycerides as well as reduced high-density lipoprotein 
cholesterol in CAD subjects compared to healthy controls 
(p < 0.05). Logistic regression analysis of the data revealed an 
association of the RR genotype of the Q192R polymorphism 
with an about 2-fold elevated risk of CAD (OR = 2.23, 95% 
CI = 1.47–3.37, p = 0.0001). Contrariwise, the L55M polymor-
phism did not show significant association with CAD (OR = 
1.81, 95% CI = 0.66–4.95, p = 0.326). Conclusions: The Q192R 
polymorphism in the PON1 gene may be a susceptibility 
gene associated with increased risk of CAD in an Asian Indian 
population. © 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Cardiovascular diseases (CVDs), including coronary 
artery disease (CAD) and stroke, have emerged as major 
health conditions associated with high mortality and pro-
nounced socioeconomic burden in the developing coun-
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tries. Currently in India, there are 270 deaths/10,000 peo-
ple from CVDs [1]. Recent estimates predict that India 
lost about USD 237 billion on healthcare expenditure in 
the last decade (2005–2015) due to the exponential in-
crease in the burden of CVDs [2]. CAD is a multifactorial 
disease in which interactions among various environmen-
tal and genetic determinants play a critical role in patho-
physiology [3, 4]. Recent studies revealed an association 
of single nucleotide polymorphisms (SNPs) in various 
genes with the augmented risk of developing CAD in 
many populations. Serum paraoxonase 1 (PON1) is one 
of the susceptibility genes which play a significant role in 
vascular pathology, and thus is regarded as an emergent 
biomarker of CAD. It is a 44-kDa Ca2+-dependent glyco-
protein enzyme produced in the liver and bound to the 
surface of high-density lipoproteins (HDLs). PON1 is re-
leased into the blood by the liver, where it associates pri-
marily with HDL [5] and is regarded to be a key factor for 
the antioxidative activity of HDL [6]. The PON1 gene has 
several SNPs [7]; however, the extensively studied SNPs 
are those in the coding regions, i.e., Q192R (rs662) and 
L55M (rs854560) [8]. The Q192R polymorphism, repre-
sented by an exchange of glutamine (Q) to arginine (R), 
may disturb the antioxidative potential of Arg192 and lead 
to greater risk of developing CAD [9]. There is another 
polymorphism of the PON1 gene, L55M, in which leucine 
to methionine substitution occurring at amino acid 55 has 
been associated with reduced PON1 activity [10]. Earlier 
studies showed that L55M genetic polymorphism may be 
related with cerebrovascular disease and CAD [11]. Some 
studies have been reported in Asian Indians, but were 
concentrated on the other parts of India. So, the present 
study was devised to examine the genetic interplay of 
PON1 gene polymorphisms (Q192R and L55M) and 
modifiable lifestyle-related factors associated with the risk 
of CAD in an Asian Indian population.
Materials and Methods
Study Subjects
The present study included 872 human subjects, among whom 
460 were healthy controls and 412 were angiographically con-
firmed CAD patients. All these subjects were a part of our ongoing 
study on diabetes and CVD [12]. In brief, this study was launched 
in year 2011 to inspect the susceptibility genes and their association 
with the pathophysiology of metabolic disorders, including type 2 
diabetes and CVDs, in an Asian Indian population. CAD was diag-
nosed by a cardiologist from the medical records showing medical 
indications, disturbed cardiac enzymes, ECG variations, and the 
outcomes of angiography and/or echocardiography. The study was 
explained to each participant and then information was collected 
regarding age, sex, educational qualifications, physical inactivity, 
diet, family history of CAD, smoking, alcohol consumption, etc.
Inclusion/Exclusion Criteria
Individuals aged > 35 years, irrespective of their disease status, 
were involved in this study. Participants belonging to north Indian 
states only (Punjab, Haryana, and Chandigarh) were included in 
this study. Controls having a family history of CVD, type 2 diabe-
tes, osteoporosis, other bone disorders, or cancer were excluded 
from the study.
Anthropometric and Clinical Measurements
Standard anthropometric measurements including height, 
weight, as well as waist and hip circumference were performed in all 
participants using standard procedures. Blood pressure was mea-
sured using an Omron blood pressure meter. Fasting blood samples 
were collected for clinical estimations, including serum glucose, to-
tal cholesterol, triglyceride, HDL, and creatinine levels using stan-
dard kits. All derived measures, including body mass index (BMI), 
body fat percentage, low-density lipoprotein (LDL) cholesterol, and 
very-low-density lipoprotein (VLDL) cholesterol, were calculated 
using standard formulae. Phenotypic characterizations, such as hy-
pertension, obesity, and dyslipidemia, were completed according to 
the values recommended for Asian Indians only.
Genotyping of the PON1 Gene
Genomic DNA was extracted from nucleated blood cells using 
phenol/chloroform/isoamyl alcohol. The PON1 gene was amplified 
to detect the Q192R polymorphism using the following primers: 
1 2 3 4 5 6 M 7 8 9 10 11 12
144 bp
122 bp 111 bp
77 bp
Fig. 1. Digested PCR product of the PON1 
(Q192R and L55M) gene polymorphism 
with HinfI restriction enzyme. Lane M: 
100-bp marker ladder; lanes 1, 2: 144 bp 
(MM); lanes 3, 4: 122 bp (LL); lanes 5, 6: 
144 bp and 122 bp (LM); lanes 7, 8: 111 bp 
(QQ); lanes 9–11: 111 bp and 77 bp (QR); 
lane 12: 77 bp (RR). PON1, paraoxonase 1.
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forward, 5′-TTG AAT GAT ATT GTT GCT GTG GGA CCT GAG-
3′; reverse, 5′-CGA CCA CGC TAA ACC CAA ATA CAT CTC 
CCA GAA-3′. The amplification was done in 20 µL reaction mixture 
containing 100–200 ng genomic DNA, 1× Taq DNA polymerase 
buffer, 2.5 mM of MgCl2, 10 pmol of each primer, 200 µmol/L of 
dNTPs, and 1 U of Taq DNA polymerase enzymes (Thermo) using 
a thermal cycler (Eppendorf). The PCR conditions were: initial de-
naturation at 94  ° C for 5 min, followed by 35 cycles of denaturation 
at 94  ° C for 45 s; annealing at 60  ° C for 45 s; and then extension 
at 72  ° C for 45 s, with a final extension step at 72  ° C for 10 min. Fig-
ure 1 (right side) shows the amplified PCR products of 111 bp di-
gested with restriction enzyme – HinfI (New England Biolabs) – and 
then resolved on 3% agarose gel electrophoresis for the Q192R ge-
notypes (QQ [111 bp], QR [111 and 77 bp], and RR [77 bp]).
For detection of the L55M gene polymorphism, we used the fol-
lowing primers: forward, 5′-GAG TGA TGT ATA GCC CCA GTT 
TC-3′; reverse, 5′-AGT CCA TTA GGC AGT ATC TCC G-3. We 
amplified the L55M gene polymorphism using similar PCR condi-
tions in a 20-µL reaction mixture. The amplified PCR product of 
144 bp was then digested with HinfI restriction enzyme at 37  ° C 
overnight. Figure 1 (left side) shows the digested product resolved 
on 3% agarose gel electrophoresis. The three genotypes were as fol-
lows: MM (144 bp), LM (144 and 122 bp), and LL (122 bp).
Statistical Analysis
Quantitative measures were expressed as mean ± standard de-
viation. One-way ANOVA was applied to compare the normally 
distributed variables among various genotypes. Categorical vari-
ables were presented as percentage of cases and analyzed with 
Pearson’s χ2 test. p values < 0.05 (two-tailed) were considered sig-
nificant. Logistic regression analysis was done to associate various 
clinical parameters with genotypes. ORs were calculated with 95% 
CIs. All statistical analyses were carried out using the Statistical 
Package for the Social Sciences for Windows (SPSS), version 20.0 
(IBM, Chicago, IL, USA).
Results
Baseline Characteristics of the Study Population
Of the 872 participants included in this study, 412 were 
angiographically proven CAD patients and 460 were 
healthy subjects. Smoking and alcohol consumption were 
significantly higher in CAD subjects compared to con-
trols (p < 0.001). Table 1 summarizes the anthropometric 
and clinical characteristics of the study subjects. The 
mean age of healthy controls and CAD patients was 56.21 
± 12.78 and 56.81 ± 10.55 years, respectively. Controls 
showed significantly higher BMI values compared to 
CAD patients (25.69 ± 4.64 vs. 24.51 ± 4.1, p < 0.001). 
Central obesity, revealed by higher waist circumference 
and waist to hip ratio, was significantly prominent in 
CAD patients compared to controls, even at normal BMI 
values recommended for Asian Indians (Table 1). Signif-
icantly higher values of body fat percentage as well as sys-
tolic and diastolic blood pressure were observed in CAD 
patients compared to controls (p < 0.001). More than 85% 
of CAD patients were regularly taking lipid-lowering 
drugs to maintain their adverse lipid profile, due to which 
CAD patients might show normal values of total choles-
terol, LDL, VLDL, and total lipids. Contrariwise, signifi-
cantly lower HDL cholesterol, total cholesterol/HDL, and 
LDL/HDL ratio were found in CAD patients compared 
to controls. Creatinine levels were significantly higher in 
CAD subjects than controls, indicating some nephrolog-
ical complications. Although fasting glucose levels in 
both controls and CAD cases were normal, elevated fast-
ing blood glucose values were observed in CAD subjects 
compared to healthy controls.
Genotype Distribution in CAD Patients and Healthy 
Controls
The distribution of genotypes and allelic frequencies 
for the Q192R polymorphism of the PON1 gene are 
shown in Table 2. The frequencies of the QQ, QR, and RR 
Table 1. Anthropometric and clinical parameters in CAD patients 
and controls
Parameters Controls CAD patients p 
valuemean SD mean SD
Age, years 56.21 12.78 56.81 10.55 0.414
Height, cm 161.96 9.28 164.77 7.86 0.000
Weight, kg 67.29 12.71 66.64 12.55 0.410
BMI, kg/m2 25.69 4.64 24.51 4.10 0.000
WC, cm 88.19 11.51 90.68 10.47 0.000
WHR 0.94 0.08 0.99 0.06 0.000
Body fat, % 32.67 10.14 29.31 9.15 0.000
Systolic BP, mm Hg 129.50 21.45 133.38 19.83 0.003
Diastolic BP, mm Hg 79.43 9.69 83.16 11.13 0.000
Glucose, mg/dL 93.03 10.99 97.08 11.10 0.000
Cholesterol, mg/dL 179.77 37.41 151.99 43.86 0.000
TGs, mg/dL 150.00 66.32 147.18 63.78 0.494
HDL, mg/dL 45.52 7.54 43.23 6.49 0.000
LDL, mg/dL 104.25 36.75 79.32 41.40 0.000
VLDL, mg/dL 30.00 13.26 29.44 12.76 0.494
Total lipids, mg/dL 509.50 112.50 451.10 124.30 0.000
TC/HDL ratio 4.06 1.13 3.60 1.24 0.000
LDL/HDL ratio 2.37 0.99 1.89 1.09 0.000
TG/HDL ratio 3.44 1.89 3.55 1.94 0.357
Creatinine, mg/dL 0.85 0.67 0.98 0.34 0.001
p values <0.05 were considered significant. BMI, body mass in-
dex; BP, blood pressure; CAD, coronary artery disease; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; SD, standard 
deviation; TC, total cholesterol; TG, triglyceride; VLDL, very-low-
density lipoprotein; WC, waist circumference; WHR, waist to hip 
ratio.
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genotypes of the PON1 gene Q192R polymorphism in 
CAD patients and controls were 37.6, 44.9, and 17.5% vs. 
51.1, 38.3, and 10.7%, respectively. A significantly higher 
frequency of RR genotype was observed in CAD patients 
than in controls (p < 0.0001). Logistic regression analysis 
of the data revealed that the heterozygous genotype (QR) 
in the PON1 gene might be associated with an about 1.6 
fold augmented risk of developing CAD in an Indian 
population (odds ratio [OR] = 1.59, 95% CI = 1.19–2.12, 
p < 0.0001), whereas the QR genotype might be associ-
ated with an about 2.2-fold augmented risk (OR = 2.23, 
95% CI = 1.47–3.37, p < 0.0001). When the data were 
stratified according to the anthropometric and biochem-
ical characteristics of all the subjects according to the 
genotypes QQ, QR, and RR of the PON1 Q192R poly-
morphism, no significant differences were observed be-
tween the genotype in CAD patients and that in controls 
(Table 3). Although an uneven distribution of some of 
the clinical parameters was observed in both cases and 
controls, all were nonsignificant.
The distribution of genotype and allelic frequencies 
for the L55M polymorphism of the PON1 gene is illus-
trated in Table 2. The frequencies of the MM, LM, and LL 
genotypes of PON1 gene L55M polymorphism in con-
trols versus CAD patients were 2.4, 31.5, and 66.1% ver-
sus 1.5, 25.7, and 72.8%, respectively. No significant dif-
ferences were prominent in the distribution of L55M ge-
notypes among the controls and CAD patients. The 
frequency of the L allele was higher than that of the M 
allele in both CAD patients and controls. Logistic regres-
sion data analysis did not establish a significant associa-
tion of the LL genotype with CAD (OR = 1.81, 95% CI = 
0.66–4.95, p = 0.326). Similar to the Q192R polymor-
phism, we stratified all anthropometric and biochemical 
characteristics of the CAD patients and controls accord-
ing to the genotypes LL, LM, and MM of the PON1 L55M 
polymorphism, but did not observe significant differenc-
es among the various genotypes in CAD patients or con-
trols (Table 4).
Discussion
The escalation of incidence and prevalence of CVDs in 
India has become a major public health issue associated 
with social, personal, and economic burden for individu-
als, families, and state healthcare system [1]. A recent 
study established a higher risk of developing CVD among 
north Indians compared to inhabitants of other parts of 
India [13]. There are many risk factors which contribute 
to the present epidemic situation of CVDs in Indian pop-
ulations. Various studies reported an association of envi-
Table 2. Distribution of genotype and allele frequencies of PON1 (Q192R and L55M) polymorphisms in CAD 
patients and controls
Genotypes Controls, 
n (f)
CAD patients, 
n (f)
Test of association
p value OR 95% CI
Q192R polymorphism
Total 460 412
QQ 235 (51.1) 155 (37.6) reference
QR 176 (38.3) 185 (44.9) <0.0001 1.59 1.19–2.12
RR 49 (10.7) 72 (17.5) <0.0001 2.23 1.47–3.37
Allele frequency
Q 0.70 0.60
R 0.30 0.40 <0.0001
L55M polymorphism
Total 460 412
MM 11 (2.4) 6 (1.5) reference
LM 145 (31.5) 106 (25.7) 0.621 1.34 0.48–3.74
LL 304 (66.1) 300 (72.8) 0.326 1.81 0.66–4.95
Allele frequency
L 0.82 0.86 0.031
M 0.18 0.14
Bold indicates statistical significance (p < 0.05). CAD, coronary artery disease; PON1, paraoxonase 1.
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Table 3. Distribution of metabolic characteristics in controls and CAD patients according to the genotypes of the 
Q192R polymorphism in the PON1 gene
Parameters Genotypes Controls CAD patients
mean SD p value mean SD p value
BMI, kg/m2 QQ 26.23 4.69 0.559 23.13 4.99 0.532
QR 25.20 4.57 23.65 3.52
RR 24.92 4.06 24.57 2.71
WC, cm QQ 90.88 9.05 0.991 89.63 15.30 0.397
QR 90.79 8.69 90.89 9.15
RR 90.47 7.59 94.31 8.52
HC, cm QQ 95.59 8.26 0.712 91.59 9.62 0.408
QR 94.05 7.76 93.21 7.24
RR 95.08 8.25 95.17 5.74
WHR QQ 0.95 0.07 0.641 0.97 0.10 0.712
QR 0.97 0.07 0.98 0.06
RR 0.95 0.07 0.99 0.07
Body fat, % QQ 34.83 10.31 0.756 29.79 9.77 0.437
QR 33.14 9.41 28.38 7.24
RR 33.89 7.34 31.30 10.59
Systolic BP, mm Hg QQ 141.75 23.53 0.112 130.40 19.63 0.249
QR 137.54 21.70 133.32 16.07
RR 125.27 19.96 140.81 24.98
Diastolic BP, mm Hg QQ 82.13 11.89 0.305 83.33 12.91 0.903
QR 83.15 11.62 82.02 9.41
RR 77.18 7.82 82.13 10.09
Glucose, mg/dL QQ 99.06 6.63 0.053 105.75 10.91 0.526
QR 97.29 9.16 99.00 11.21
RR 91.80 8.16 99.33 9.59
Cholesterol, mg/dL QQ 184.38 36.63 0.385 143.33 39.93 0.621
QR 186.05 34.89 134.84 42.52
RR 201.45 40.14 145.00 49.93
TGs, mg/dL QQ 134.59 37.83 0.126 160.67 55.60 0.662
QR 158.44 58.17 150.20 45.92
RR 146.27 38.87 161.15 73.76
HDL, mg/dL QQ 43.44 2.59 0.390 42.33 4.20 0.473
QR 42.62 3.22 43.48 3.44
RR 43.64 2.66 43.72 3.05
LDL, mg/dL QQ 114.02 36.87 0.380 68.87 36.78 0.713
QR 111.75 33.23 61.32 41.31
RR 128.56 40.70 69.05 48.26
VLDL, mg/dL QQ 26.92 7.57 0.126 32.13 11.12 0.662
QR 31.69 11.64 30.04 9.19
RR 29.25 7.77 32.23 14.75
Total lipids, mg/dL QQ 503.30 86.90 0.324 447.30 119.90 0.528
QR 530.50 106.80 419.80 109.80
RR 549.20 98.40 451.10 142.50
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ronmental risk factors with the development of CVDs 
[14, 15]. In our previous study, we presented abdominal 
obesity, even at normal BMI, dyslipidemia, family history 
of CAD, and cigarette smoking as independent risk fac-
tors for CAD in north Indians [16]. It was evident from 
earlier studies that Asian Indians develop CAD in the 
most dynamic period of their life and at least a decade 
earlier than Caucasians [17].
Several studies have documented the role of SNPs 
in various genes in the escalating risk of CAD [18, 
19]. PON1 is known to play important roles such as an 
antioxidant, anti-inflammatory, and antiatherosclerotic 
functions by preventing LDL oxidation [20]. Moreover, 
PON1 inhibits the accumulation of oxidized LDL and 
speeds up cholesterol efflux from macrophages [21, 22]. 
Some studies extensively studied the Q192R and L55M 
polymorphisms in PON1 in different populations and 
exhibited the pathogenesis of CVDs [23]. PON1 may be 
atheroprotective [24, 25], and genetic variations in the 
PON1 gene may affect its ability to protect against CVDs. 
The present study established an association of the RR 
genotype of the Q192R polymorphism with a two-fold 
amplified risk of CAD in a north Indian population. 
Also, the frequency of mutant allele (R) in the 192R-
PON1 gene among CAD patients was comparable to that 
in previous studies conducted in Indian populations. 
Our results are in line with an earlier study done in a 
northwest Punjabi population where the QR and RR 
genotypes contributed to increased CAD development 
[26]. Many other studies documented a relationship of 
the Q192R polymorphism with an increased risk of CAD 
in Asian Indian populations [10, 27–31], Caucasians [9, 
32], and Japanese [33], but negative results have been re-
ported in Korean [34], Spanish [35], Italian [36], British 
Caucasian [37, 38], and Polish [39] populations. Meta-
analyses of various studies also confirmed an association 
of the 192R variant with the risk of CAD development 
[40, 41]. However, no significant association of the 192R 
genotype with CAD was reported in a Taiwanese popula-
tion [42]. Interestingly, various Asian, Indian, European 
Caucasian, and Saudi Arabian populations revealed 
comparable frequency of the alleles [43], while some Af-
rican black populations have a significantly higher fre-
quency of the PON1 192Q allele [44]. These inconsisten-
cies in the association of the Q192R genotype with high 
CAD risk may be due to sample size, differences in eth-
nicity, genotyping methods, as well as gene-gene and 
gene-environment interactions [43]. We did not find any 
significant association of the RR genotype in the PON1 
gene with metabolic traits in CAD patients or controls. 
Table 3 (continued)
Parameters Genotypes Controls CAD patients
mean SD p value mean SD p value
TC/HDL ratio QQ 4.27 0.95 0.510 3.47 1.18 0.594
QR 4.41 1.00 3.16 1.16
RR 4.67 1.19 3.37 1.30
LDL/HDL ratio QQ 2.64 0.92 0.516 1.68 0.96 0.683
QR 2.66 0.88 1.45 1.04
RR 3.00 1.10 1.61 1.17
TG/HDL ratio QQ 3.12 0.95 0.101 3.92 1.72 0.648
QR 3.78 1.56 3.53 1.43
RR 3.38 1.06 3.80 2.12
Creatinine, mg/dL QQ 0.92 1.88 0.590 0.95 0.31 0.892
QR 0.71 0.33 0.94 0.37
RR 0.53 0.17 0.99 0.40
p values denote differences among the genotypes in a particular condition. p values <0.05 were considered 
significant. BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; HC, hip circumference; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; PON1, paraoxonase 1; SD, standard deviation; TC, 
total cholesterol; TG, triglyceride; VLDL, very-low-density lipoprotein; WC, waist circumference; WHR, waist 
to hip ratio.
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Table 4. Distribution of metabolic characteristics in controls and CAD patients according to the genotypes of the 
L55M polymorphism in the PON1 gene
Parameters Genotypes Controls CAD patients
mean SD p value mean SD p value
BMI, kg/m2 LL 25.05 6.02 0.824 23.57 1.97 0.412
LM 22.87 3.87 22.81 3.09
MM 24.13 7.46 24.31 3.99
WC, cm LL 88.95 13.40 0.646 92.89 6.77 0.224
LM 95.52 12.91 86.59 7.63
MM 89.08 16.56 92.18 11.24
HC, cm LL 92.52 12.95 0.546 93.70 5.28 0.430
LM 94.52 7.75 91.02 6.03
MM 88.71 10.25 94.65 9.42
WHR LL 0.96 0.04 0.661 0.99 0.06 0.286
LM 1.01 0.08 0.95 0.06
MM 1.00 0.13 0.97 0.06
Body fat, % LL 33.50 9.07 0.383 26.57 4.35 0.105
LM 33.78 6.30 27.44 8.01
MM 26.91 13.47 31.73 10.28
Systolic BP, mm Hg LL 122.00 13.04 0.235 134.29 12.23 0.864
LM 132.86 26.33 137.36 14.89
MM 116.25 10.61 136.88 18.27
Diastolic BP, mm Hg LL 79.00 18.84 0.684 83.57 11.51 0.762
LM 83.00 9.56 85.73 8.39
MM 76.88 12.80 83.34 9.64
Glucose, mg/dL LL 102.50 2.12 0.388 101.67 18.93 0.398
LM 87.60 10.78 92.17 9.30
MM 90.40 15.08 98.68 11.19
Cholesterol, mg/dL LL 163.29 12.76 0.531 138.44 55.33 0.856
LM 148.00 35.46 135.45 47.03
MM 141.77 38.74 143.11 44.15
TGs, mg/dL LL 142.28 18.85 0.928 150.56 73.86 0.248
LM 134.14 48.13 124.91 27.46
MM 143.85 63.84 156.47 56.17
HDL, mg/dL LL 42.09 5.68 0.101 43.35 3.99 0.798
LM 47.29 4.96 42.36 3.61
MM 40.99 5.90 42.52 4.61
LDL, mg/dL LL 92.74 19.85 0.419 64.98 55.42 0.948
LM 73.89 29.39 68.11 46.78
MM 72.01 31.85 69.29 40.76
VLDL, mg/dL LL 28.46 3.77 0.928 30.11 14.77 0.248
LM 26.83 9.63 24.98 5.49
MM 28.77 12.77 31.29 11.23
Total lipids, mg/dL LL 468.80 21.90 0.769 427.40 145.10 0.529
LM 430.10 109.10 395.80 109.50
MM 427.30 131.21 442.60 125.90
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However, previous findings proved an association be-
tween serum triglyceride levels and RR genotype [45–
47]. It is not clearly ascertained by which mechanism 
PON1 polymorphisms affect the level of serum triglycer-
ides.
The present study did not show a significant associa-
tion of PON1 (L55M) polymorphism with the risk of 
CAD in Asian Indians. Our results agreed with earlier 
studies showing that PON1-55 independently has no 
consequence on CAD [10, 30, 40]. Contrariwise, a study 
proposed the protective effect of the M allele of PON1 
against CAD [48]. The LL genotype was observed to be a 
genetic risk factor for carotid atherosclerosis [49]. An-
other study observed a higher frequency of the PON1 L 
allele in CAD patients, thus establishing a significant con-
nection of PON1 L55M polymorphism with CAD [50]. 
Some of the studies that were accomplished to demon-
strate the relationship between the PON1-L55M poly-
morphism and CAD showed conflicting results [51]. In 
an Austrian population, it was seen that the L55M poly-
morphism was linked with CAD [49], whereas studies in 
other populations showed inconsistent results [30]. Our 
study showed a negative correlation between the L55M 
locus and CAD risk, and only the M allele was concluded 
to be a risk allele.
Conclusions
The present study demonstrated a significant associa-
tion of the Q192R polymorphism in the PON1 gene with 
an increased risk of CAD, whereas no significant associa-
tion was observed between the L55M polymorphism and 
CAD. Furthermore, metabolic traits were unaffected by 
variants of the PON1 gene in Asian Indians.
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Table 4 (continued)
Parameters Genotypes Controls CAD patients
mean SD p value mean SD p value
TC/HDL ratio LL 3.97 0.86 0.373 3.26 1.43 0.850
LM 3.16 0.83 3.27 1.36
MM 3.53 1.11 3.44 1.22
LDL/HDL ratio LL 2.29 0.85 0.321 1.55 1.34 0.921
LM 1.58 0.66 1.67 1.27
MM 1.82 0.85 1.69 1.05
TG/HDL ratio LL 3.39 0.20 0.616 3.58 2.13 0.353
LM 2.90 1.17 2.97 0.76
MM 3.59 1.83 3.77 1.67
Creatinine, mg/dL LL 1.05 0.17 0.197 0.85 0.17 0.197
LM 0.95 0.19 0.92 0.19
MM 3.26 4.08 0.98 0.27
p values denote differences among the genotypes in a particular condition. p values <0.05 were considered 
significant. BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; HC, hip circumference; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; PON1, paraoxonase 1; SD, standard deviation; TC, 
total cholesterol; TG, triglyceride; VLDL, very-low-density lipoprotein; WC, waist circumference; WHR, waist 
to hip ratio.
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